- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sage Therapeutics Seeks FDA Approval for Brexanolone in Postpartum Depression
The company has previously received breakthrough therapy designation for the treatment.
Sage Therapeutics today submitted a new drug application (NDA) to the FDA for intravenous brexanolone, which has already received breakthrough therapy designation for the treatment of postpartum depression (PPD). The company announced the filing in a statement.
Brexaolone IV, the company’s first NDA, has succeeded in 2 phase 3 trials at beating placebo in reducing patients’ symptoms of PPD, a condition that affects an average of 11.5% of new mothers each year. The intravenous form of the drug requires a 60-hour infusion. Sage Therapeutics is also developing a pill form of the drug.
The drug is an allosteric modulator of both synaptic and extrasynaptic GABAA receptors, proteins that were revealed as the potential target of a PPD treatment a decade ago in experiments with mice at the University of California Los Angeles. These preclinical experiments showed that the GABAA fell during pregnancy to keep the body in sync with neurosteroid levels, and then rose after birth. But if dysregulation occurs, the depression ensues.
PPD can cause significant functional impairment for women and their families, and the condition can include lack of interest in the newborn, loss of appetite, difficulty sleeping, and lack of concentration. Right now, there are no FDA-approved therapies for the condition and significant unmet need.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
